Literature DB >> 25824902

A meta-analysis of immunogenetic Case-Control Association Studies in irritable bowel syndrome.

B Czogalla1, S Schmitteckert, L A Houghton, G S Sayuk, M Camilleri, A Olivo-Diaz, R Spiller, M M Wouters, G Boeckxstaens, J Lorenzo Bermejo, B Niesler.   

Abstract

BACKGROUND: To date, genetic-association studies of single nucleotide polymorphisms (SNP) in selected candidate genes with the symptom phenotype of irritable bowel syndrome (IBS) have typically involved hundreds to 2000 patients. SNPs in immune-related genes, such as cytokine and cytokine receptor encoding genes, have been reported to associate with IBS risk.
METHODS: We conducted two independent case-control studies on 16 SNPs in IL1R1, IL4, IL6, IL8, IL10, IL23R, TNFA, and TNFSF15, one from the UK (194 patients and 92 healthy volunteers) and one from the USA (137 patients and 96 healthy volunteers). The main aim was to examine the relationship between inherited immunological diversity and IBS risk in a meta-analysis which included 12 additional, earlier studies. The meta-analysis comprised a total of 2894 patients (839 IBS-C, 1073 IBS-D, 502 IBS-M), and 3138 healthy volunteers with self-reported Caucasian ancestry. KEY
RESULTS: The association of SNP rs4263839 (TNFSF15) was investigated in four studies and confirmed in the meta-analysis: IBS (OR 1.19, 95% CI 1.08-1.31), and IBS-C (OR 1.24, 95% CI 1.08-1.42). No additional SNPs residing in immunogenes associated with IBS symptom phenotypes. CONCLUSIONS & INFERENCES: Our meta-analysis could not confirm a major role of most investigated SNPs, but a moderate association between rs4263839 TNFSF15 and IBS, in particular IBS-C. The analysis emphasizes the importance of definition and phenotype homogeneity, adequate study size and representativeness of the patient and control collective.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  SNP; cytokine; cytokine receptor; irritable bowel syndrome; meta-analysis

Mesh:

Substances:

Year:  2015        PMID: 25824902     DOI: 10.1111/nmo.12548

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  17 in total

Review 1.  Pharmacogenetics and the treatment of functional gastrointestinal disorders.

Authors:  Houssam Halawi; Michael Camilleri
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

Review 2.  IBS and IBD - separate entities or on a spectrum?

Authors:  Robin Spiller; Giles Major
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-09-26       Impact factor: 46.802

3.  Immune Activation in Functional Gastrointestinal Disorders.

Authors:  Grace Burns; Jennifer Pryor; Gerald Holtmann; Marjorie M Walker; Nicholas J Talley; Simon Keely
Journal:  Gastroenterol Hepatol (N Y)       Date:  2019-10

4.  The serotonin receptor 3E variant is a risk factor for female IBS-D.

Authors:  Nikola Fritz; Sabrina Berens; Yuanjun Dong; Cristina Martínez; Stefanie Schmitteckert; Lesley A Houghton; Miriam Goebel-Stengel; Verena Wahl; Maria Kabisch; Dorothea Götze; Mauro D'Amato; Tenghao Zheng; Ralph Röth; Hubert Mönnikes; Jonas Tesarz; Felicitas Engel; Annika Gauss; Martin Raithel; Viola Andresen; Jutta Keller; Thomas Frieling; Christian Pehl; Christoph Stein-Thöringer; Gerard Clarke; Paul J Kennedy; John F Cryan; Timothy G Dinan; Eamonn M M Quigley; Robin Spiller; Caroll Beltrán; Ana María Madrid; Verónica Torres; Emeran A Mayer; Gregory Sayuk; Maria Gazouli; George Karamanolis; Mariona Bustamante; Xavier Estivil; Raquel Rabionet; Per Hoffmann; Markus M Nöthen; Stefanie Heilmann-Heimbach; Börge Schmidt; André Franke; Wolfgang Lieb; Wolfgang Herzog; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Gudrun A Rappold; Maria Vicario; Javier Santos; Rainer Schaefert; Justo Lorenzo-Bermejo; Beate Niesler
Journal:  J Mol Med (Berl)       Date:  2022-09-19       Impact factor: 5.606

Review 5.  Review article: biomarkers and personalised therapy in functional lower gastrointestinal disorders.

Authors:  M Camilleri
Journal:  Aliment Pharmacol Ther       Date:  2015-08-11       Impact factor: 8.171

6.  2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome.

Authors:  Lin Chang; Margaret M Heitkemper; John W Wiley; Michael Camilleri
Journal:  Gastroenterology       Date:  2016-05-20       Impact factor: 22.682

7.  Genetics of irritable bowel syndrome.

Authors:  Maria Henström; Mauro D'Amato
Journal:  Mol Cell Pediatr       Date:  2016-02-12

8.  2015 James W. Freston Single Topic Conference: A Renaissance in the Understanding and Management of Irritable Bowel Syndrome.

Authors:  Lin Chang; Margaret M Heitkemper; John W Wiley; Michael Camilleri
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2016-05-28

Review 9.  Current insights into the innate immune system dysfunction in irritable bowel syndrome.

Authors:  Nikolaos Lazaridis; Georgios Germanidis
Journal:  Ann Gastroenterol       Date:  2018-01-18

10.  The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome.

Authors:  Sandra Mohr; Nikola Fritz; Christian Hammer; Cristina Martínez; Sabrina Berens; Stefanie Schmitteckert; Verena Wahl; Malin Schmidt; Lesley A Houghton; Miriam Goebel-Stengel; Maria Kabisch; Dorothea Götze; Irina Milovač; Mauro D'Amato; Tenghao Zheng; Ralph Röth; Hubert Mönnikes; Felicitas Engel; Annika Gauss; Jonas Tesarz; Martin Raithel; Viola Andresen; Thomas Frieling; Jutta Keller; Christian Pehl; Christoph Stein-Thöringer; Gerard Clarke; Paul J Kennedy; John F Cryan; Timothy G Dinan; Eamonn M M Quigley; Robin Spiller; Caroll Beltrán; Ana María Madrid; Verónica Torres; Edith Pérez de Arce; Wolfgang Herzog; Emeran A Mayer; Gregory Sayuk; Maria Gazouli; George Karamanolis; Lejla Kapur-Pojskič; Mariona Bustamante; Raquel Rabionet; Xavier Estivil; André Franke; Wolfgang Lieb; Guy Boeckxstaens; Mira M Wouters; Magnus Simrén; Gudrun A Rappold; Maria Vicario; Javier Santos; Rainer Schaefert; Justo Lorenzo-Bermejo; Beate Niesler
Journal:  J Cell Mol Med       Date:  2021-06-24       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.